Synthesis and biological properties of bioreductively targeted nitrothienyl prodrugs of combretastatin A-4

Molecular Cancer Therapeutics

Volumn 5, Issue 11, 2006, Pages 2886-2894

  Thomson, Peter ^a   Naylor, Matthew A ^a   Everett, Steven A ^a   Stratford, Michael R L ^a   Lewis, Gemma ^a   Hill, Sally ^a   Patel, Kantilal B ^a   Wardman, Peter ^a   Davis, Peter D ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b Angiogene Pharmaceuticals Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

(4 METHYLCOUMARIN 7 YL)OXYMETHYL 5 NITROTHIOPHENE; 1 [4 METHOXY 3 (5 NITROTHIEN 2 YL)METHYLOXY]PHENYL 2 (3,4,5 TRIMETHOXY)PHENYL ETHENE; 1 [4 METHOXY 3 [1 [1 (5 NITROTHEIN 2 YL)]ETHOXY]]PHENYL 2 (3,4,5 TRIMETHOXY)PHENYL ETHENE; 1 [4 METHOXY 3 [2 (5 NITROTHIEN 2 YL)PROP 2 YLOXY]]PHENYL 2 (3,4,5 TRIMETHOXY)PHENYL ETHENE; 2 (1 BROMOETHYL) 5 NITROTHIOPHENE; 2 (5 NITROTHIEN 2 YL)PROPAN 2 OL; 2 [ 1 METHYL 1 (4 METHYLCOUMARIN 7 YL)OXY]ETHYL 5 NITROTHIOPHENE; 2 [1 (4 METHYLCOUMARIN 7 YL)OXY]ETHYL 5 NITROTHIOPHENE; 2 BROMOMETHYL 5 NITROTHIOPHENE; 2 THIEN 2 YL PROPAN 2 OL; ANION; CARBOXYL GROUP; COMBRETASTATIN A4; COMBRETASTATIN A4 PHOSPHATE; ETHYL 2 (4 METHYLCOUMARIN 7 YL)OXY 2 (5 NITROTHIEN 2 YL)PROPANOATE; ETHYL 2 [2 METHOXY 5 [2 (3,4,5 TRIMETHOXYPHENYL)VINYL]]PHENOXY 2 (5 NITROTHIEN 2 YL)PROPANOATE; METHYL GROUP; OXYGEN; PRODRUG; RADICAL; THIOPHENE DERIVATIVE;

AEROBIC METABOLISM; ANIMAL CELL; ANOXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL SUSPENSION; CONTROLLED STUDY; CYTOTOXICITY; DRUG RELEASE; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; EXPERIMENTAL DESIGN; HYPOXIA; IN VITRO STUDY; MOUSE; NONHUMAN; OXYGEN CONCENTRATION; PRIORITY JOURNAL; PROCESS OPTIMIZATION; SOMATIC CELL; STRUCTURE ANALYSIS; WHOLE CELL;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LIVER; MICE; NITRO COMPOUNDS; PRODRUGS; STILBENES; THIOPHENES; TIME FACTORS; TUBULIN; TUMOR CELLS, CULTURED;

EID: 33845189883     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0429     Document Type: Article

References (47)

1. Pettit GR, Singh SB, Niven ML, Hamel E, Schmidt JM. Isolation, structure, and synthesis of combretastatins A-1 and B-1, potent new inhibitors of microtubule assembly, derived from Combretum caffrum. J Nat Prod 1987;50:119-31.
2. Pettit GR, Singh SB, Niven ML, Hamel E, Schmidt JM. Isolation, structure and synthesis of combretastatins A-1 and B-1, potent new inhibitors of microtubule assembly, derived from Combretum caffrum. J Nat Prod 1987;50:119-31.
3. Pettit GR, Singh SB, Boyd MR, et al. Antineoplastic agents. 291. Isolation and synthesis of combretastatins A-4, A-5, and A-6. J Med Chem 1995;38:1666-72.
4. Chaplin DJ, Pettit GR, Hill SA. Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anticancer Res 1999;19:189-95.
5. Folkman J. Angiogenesis in cancer, vascular, rheumatoid, and other diseases. Nat Mad 1995;1:27-31.
6. Lin CM, Singh SB, Chu PS, et al. Interactions of tubulin with potent natural and synthetic analogues of the antimitotic agent combretastatin: a structure-activity study. Mol Pharmacol 1988;34:200-8.
7. Dark GG, Hill SA, Prise VE, et al. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 1997;57:1829-34.
8. Tozer GM, Prise VE, Wilson J, et al. Mechanisms associated with tumour vascular shutdown induced by combretastatin A4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res 2001;61:6413-22.
9. Woods JA, Hadfield JA, Pettit GR, Fox BW, McGowan AT. The interaction with tubulin of a series of stilbenes based on combretastatin A-4. Br J Cancer 1995;71:705-11.
10. Watts ME, Woodcock M, Arnold S, Chaplin DJ. Effects of novel and conventional anti-cancer agents on human endothelial permeability: influence of tumour secreted factors. Anticancer Res 1997; 17:71-5.
11. Chaplin DJ, Hill SA. The development of CA4P as a vascular-targeting agent. Int J Radiat Oncol Biol Phys 2002;54:1472.
12. Dowlatti A, Robertson K, Cooney M, et al. A phase I pharmacokinetic and translational study of the novel vascular-targeting agent CA4P on a single dose intravenous schedule in patients with advanced cancer. Cancer Res 2002;62:3408-16.
13. Rustin GJS, Galbraith SM, Anderson H, et al. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 2003;21:2815-22.
14. Oshumi K, Nakagawa R, Fukuda Y, et al. Novel combretastatin analogues effective against murine solid tumours: design and structure-activity relationships. J Med Chem 1998;41:3022-32.
15. Maya A, Rey BD, DeClairac RP, et al. Design, synthesis, and cytotoxic activities of naphthyl analogues of combretastatin A-4. Bioorg Med Chem Lett 2000;10:2549-51.
16. Pinney KG, Mejia MP, Villalobos VM, et al. Synthesis and biological evaluation of aryl azide derivatives of combretastatin A-4 as molecular probes for tubulin. Bioorg Mad Chem 2000;8:2417-25.
17. Pettit GR, Anderson CR, Herald DL, et al. Antineoplastic agents. 487. Synthesis and biological evaluation of the antineoplastic agent 3,4-methylenedioxy-5,4′-dimethoxy-3′-amino-Z-stilbene and derived amino acid amides. J Mad Chem 2003;46:525-31.
18. McGowan AT, Fox BW. Differential cytotoxicity of the combretastatins A1 and A4 in two daunorubicin P388 resistant cell lines. Cancer Chermother Pharmacol 1990;26:79-81.
19. El-Zayat AAE, Degan D, Drabek S, et al. In vitro evaluation of the antineoplastic activity of combretastatin A4, a natural product from Combretum caffrum (arid shrub). Anticancer Drugs 1993;4:19-25.
20. Oshumi K, Hatanaka R, Nakagawa R, et al. Synthesis and antitumour activities of amino acid prodrugs of amino-combretastatins. Anticancer Drug Des 1999;14:539-48.
21. Pettit GR, Minardi MD, Boyd MR, Pettit RK. Antineoplastic agents 463. Synthesis of combretastatin A-3 diphosphate prodrugs. Anticancer Drug Des 2000; 15:397-403.
22. Pettit GR, Lippert JW III. Antineoplastic agents 429. Syntheses of the combretastatin A-1 and combretastatin B-1 prodrugs. Anticancer Drug Des 2000;15:203-16.
23. Boehle AS, Sipos B, Kliche U, Kalthoff H, Dohrmann P. Combretastatin A-4 prodrug inhibits growth of human non-small cell lung cancer in a murine xenotransplant model. Ann Thorac Surg 2001;71:1657-65.
24. Pettit GR, Moser BR, Boyd MR, et al. Antineoplastic agents. 460. Synthesis of combretastatin A2 prodrugs. Anticancer Drug Des 2001;16: 185-93.
25. Ohno T, Kawano K, Tahara K, et al. Antitumour effect of combretastatin A-4 derivative AC7700 against rat liver cancer. Gastroenterology 2001;120:2831.
26. Naylor MA, Swann E, Everett SA, et al. Indolequinone anti-tumour agents: reductive activation and elimination from (5-methoxy-1-methyl-4,7-dioxo-indol-3-yl)methyl derivatives and hypoxia-selective cytotoxicity in vitro. J Med Chem 1998;41:2720-31.
27. Everett SA, Naylor MA, Nolan J, Patel KB, Wardman P. Indolequinone bioreductive drugs: kinetic factors which influence selectivity for hypoxia. Anticancer Drug Des 1998; 13:635-53.
28. Everett SA, Swann E, Naylor MA, et al. Modifying rates of reductive elimination of leaving groups from indolequinone prodrugs: a key factor in controlling hypoxia-selective drug release. Biochem Pharmacol 2002;63:1629-39.
29. Tercel MT, Wilson WR, Anderson RF, Denny WA. Hypoxia-selective antitumor agents. 12. Nitrobenzyl quaternary salts as bioreductive prodrugs of the alkylating agent mechlorethamine. J Med Chem 1996; 39:1084-94.
30. Tercel M, Lee AE, Hogg A, et al. Hypoxia-selective antitumor agents. 16. Nitroarylmethyl quaternary salts as bioreductive prodrugs of the alkylating agent mechlorethamine. J Med Chem 2001;44:3511-22.
31. Everett SA, Naylor MA, Patel KB, Stratford MRL, Wardman P. Bioreductively-activated prodrugs for targeting hypoxic tissues: elimination of aspirin from 2-nitroimidazole derivatives. Bioorg Med Chem Lett 1999;9:1267-72.
32. Hay MP, Wilson WR, Denny WA. Nitrobenzyl carbamate prodrugs of enediynes for nitroreductase gene-directed enyzyme prodrug therapy (GDEPT). Bioorg Med Chem Lett 1999;9:3417-22.
33. Hay MP, Sykes BM, Denny WA, Wilson WR. A 2-nitroimidazole carbamate prodrug of 5-amino-1-(chloromethyl)-3-[5,6,7- trimethoxyindol-2-yl)carbonyl]-1,2-dihydro- 3H-benz[elindole (amino-seco-CBI-TMI) for use with ADEPT and GDEPT. Bioorg Med Chem Lett 1999;9:2237-42.
34. Damen EWP, Nevalainen TJ, Bergh TJMvd, Groot FMHd, Scheeren HW. Synthesis of novel paclitaxel prodrugs designed for bioreductive activation in hypoxic tumour tissue. Bioorg Mad Chem 2002; 10:71-7.
35. Borch RF, Liu J, Schmidt JP, et al. Synthesis and evaluation of nitroheterocyclic phosphoramidites as hypoxia-selective alkylating agents. J Med Chem 2000;43:2258-65.
36. Steinberg G, Borch RF. Synthesis and evaluation of pteroic acid-conjugated nitroheterocyclic phosphoramidites as folate receptor-targeted alkylating agents. J Mad Chem 2001;44:69-73.
37. Wardman P. Reduction potentials of one-electron couples involving free radicals in aqueous solution. J Phys Chem Ref Data 1989;18:1637.
38. Threadgill MD, Webb P, O'Neill P, et al. Synthesis of a series of nitrothiophenes with basic or electrophilic substituents and evaluation as radiosensitizers and as bioreductively activated cytotoxins. J Med Chem 1991;34:2112-20.
39. Naylor MA, Thomson P. Recent advances in bioreductive drug targeting. Mini Rev Med Chem 2001;1:17-29.
40. Pettit GR, Rhodes MR. Antineoplastic agents 389. New syntheses of the combretastatin A-4 prodrug. Anticancer Drug Des 1998;13: 183-91.
41. Carella A, Castaldo A, Centore R, et al. Synthesis and second order nonlinear optical properties of new chromophores containing 1,3,4-oxadiazole and thiophene rings. J Chem Soc Perk Trans 2002;2:1791-5.
42. Newcombe PJ, Norris RK. Substitution reactions of nitrothiophenes. III. Radical and ionic reactions of 4- and 5-nitro-2-thienyl-methyl and -ethyl chlorides and acetates. Aust J Chem 1979;32:2647-58.
43. Lawrence NJ, Lamarche O, Thurrub N. The facile synthesis of α-aryl-α-hydroxy esters via one-pot vicarious nucleophilic substitution and oxidation. J Chem Soc Chem Commun 1999;689-90.
44. Dullaghan ME, Owen LJ, Nord FF. 5-Nitro-2-thenaldehyde. J Am Chem Soc 1952;74:2676-7.
45. Newcombe PJ, Norris RK. Substitution reactions of nitrothiophenes with the 2-nitropropan-2-ide ion. Aust J Chem 1978;31:2463-76.
46. Candeias LP, Folkes LK, Porssa M, Parrick J, Wardman P. Rates of reaction of indoleacetic acids with horseradish peroxidase compound I and their dependence on the redox potentials. Biochemistry 1996;35: 102-8.
47. Mitsunobu O. The use of diethyl azodicarboxylate and triphenylphosphine in synthesis and transformation of natural products. Synthesis 1981;1-28.